Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

Journal of Translational Medicine

Oral Presentation

Yulei Wang¹  Yibing Yan¹  Nicholas Choong¹  Matthew Wongchenko¹  Grant McArthur²  Omid Hamid³  Antoni Ribas⁴  Thomas Gajewski⁵  Rene Gonzalez⁶  Igor Puzanov⁷ 

[1] Genentech, South San Francisco, CA, USA;Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;The Angeles Clinic and Research Institute, Los Angeles, CA, USA;The Jonsson Comprehensive Cancer Center at University of California, Los Angeles, CA, USA;University of Chicago, Chicago, USA;University of Colorado Comprehensive Cancer Center, Aurora, CO, USA;Vanderbilt-Ingram Cancer Center, Nashville, TN, USA;

关键词: MAPK Pathway;    PI3K Pathway;    Vemurafenib;    BRAF Inhibition;    Transcriptional Output;   

DOI  :  10.1186/1479-5876-12-S1-O12

来源: Springer

【 授权许可】

Unknown   
© Yan et al; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.